2015-2017 ACBS Child Combined Prevalence Tables

Table 8

Estimated percent using inhaled short acting beta agonists among children 1 with current 2 asthma status by state/territory – BRFSS Asthma Call-back Survey, United States, 2015-2017.

Table 8: BRFSS Asthma Call-Back survey 2015-2017
State/Territory Current
Sample
size±
% SE§ 95% CI
California 101 50.1 6.2 (37.9 – 62.3)
Connecticut 152 58.4 5.0 (48.6 – 68.2)
Florida 229 26.9 5.0 (17.1 – 36.7)
Georgia 100 33.6 6.1 (21.6 – 45.6)
Hawaii 82 32.0 7.2 (17.9 – 46.1)
Indiana 124 46.4 6.7 (33.3 – 59.5)
Kansas 245 55.9 3.8 (48.5 – 63.3)
Maine 132 48.0 7.3 (33.7 – 62.3)
Michigan 192 48.3 4.4 (39.7 – 56.9)
Minnesota 228 41.4 4.2 (33.2 – 49.6)
Missouri 68 46.7 7.2 (32.6 – 60.8)
Montana 72 59.1 8.8 (41.9 – 76.3)
Nebraska 197 47.8 5.6 (36.8 – 58.8)
New Jersey 202 32.4 4.8 (23.0 – 41.8)
New Mexico 105 48.9 6.9 (35.4 – 62.4)
New York 95 37.1 7.1 (23.2 – 51.0)
Ohio 157 43.8 6.4 (31.3 – 56.3)
Oregon 68 67.7 7.1 (53.8 – 81.6)
Pennsylvania 85 52.1 7.5 (37.4 – 66.8)
Rhode Island 69 54.0 7.6 (39.1 – 68.9)
Utah 191 51.7 4.6 (42.7 – 60.7)
Vermont 81 50.1 7.1 (36.2 – 64.0)
Wisconsin 42 65.7 9.5 (47.1 – 84.3)
Puerto Rico 143 15.8 4.1 (7.8 – 23.8)
24 States / Area 3,160 43.1 1.8 (39.6 – 46.6)
Median 48.2
Range 15.8-67.7

1 Aged < 18 years

2 “Yes” response to “Do you still have asthma?”

± Sample size is for multiple years of participation. Responses of “Don’t Know” and “Refused” are excluded.

§ Standard error

Confidence interval

Link for Summary Data Quality Report: https://www.cdc.gov/brfss/acbs/2017/pdf/sdq_report_acbs_17-508.pdfpdf iconpdf icon